Skip to main content

Posts

Showing posts from June, 2018

Microbots Deliver Stem Cells in the Body

The astonishing thing about stem cells is that they can be coaxed, in the laboratory, into becoming nearly any kind of cell—from bone marrow to heart muscle. That remarkable capability has for years kept scientists busy tinkering with stem cells and injecting them into animal models in an attempt to grow and replace damaged tissue.   Such scientists have received a ton of attention in that line of work. But there’s a smaller group of researchers working, to far less fanfare, on a different part of the stem cell challenge: how to deliver those cells to the body’s hard-to-reach places. Researchers typically deliver stem cells via injection—a needle. But that method can damage healthy tissue, especially when the target is a deep brain structure, or delicate vasculature, or the inner ear. A group out of Hong Kong announced this week that they had invented a new delivery tool using tiny, magnetically-controlled robots. The cell-carrying machines move noninvasively...

सबसे छोटे पंप से धमनियों के 90% ब्लॉकेज को किया गया ठीक

Patient with 90 Percent Blockage of Arteries Saved with Miniature Pump हार्ट को रिकवरी करने में मददगार दुनिया का सबसे छोटे साइज का मिनिएचर हार्ट पंप का इस्तेमाल फोर्टिस एस्कॉर्टस हार्ट इंस्टिट्यूट में किया गया। दावा है कि देश में इस डिवाइस का इस्तेमाल पहली बार किया गया है, जो हार्ट में ब्लॉकेज और लगातार खराब हो रहे हार्ट से जूझने वाले लोगों के लिए वरदान साबित हो सकता है। यह एक प्रकार से जिंदगी बचाने वाला डिवाइस है, जो हार्ट फेल होने पर रिकवरी करने में मदद करता है। फोर्टिस के कार्डियॉल्जिस्ट डॉक्टर अशोक सेठ की टीम ने इम्पेला हार्ट पंप की मदद से देश में पहली बार प्रोटेक्टेड एंजियोप्लास्टी और स्टेंटिंग प्रसीजर को सफलतापूर्वक अंजाम दिया।  धमनियों में था 90 प्रतिशत ब्लॉकेज  26 जून को यह डिवाइस 86 साल के एक मरीज में लगाया गया, जो लगातार सीने में दर्द और हार्ट अटैक की बीमारी से जूझ रहे थे। उनकी धमनियों में 90 प्रतिशत तक ब्लॉकेज था। सर्जरी में काफी खतरा था, इसलिए इस डिवाइस की मदद से एंजियोप्लास्टी की गई। 5 स्टेंट लगाने पर मरीज की रिकवरी हो गई तो 5 घंटे बाद डिवाइस क...

Lethal Prostate Cancer Treatment May Benefit From Combination Immunotherapy

Researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy (BKI) released a study investigating the use of combination checkpoint immunotherapy in the treatment of a lethal form of advanced prostate cancer. The study suggested a genetic subset of prostate cancer may benefit from this form of immunotherapy. The study targeted AR-V7+ prostate cancer with a combination of two checkpoint blockers, ipilimumab and nivolumab, in 15 patients with this aggressive variant, first discovered at Johns Hopkins in 2014. This is the first clinical trial to target this specific form of prostate cancer, which can kill patients in only six to nine months and has inadequate treatment options. It is the first reported study of combination immunotherapy using both ipilimumab and nivolumab in prostate cancer. "This is the first prostate cancer study to be supported by the Bloomberg~Kimmel Institute for Cancer Immunotherapy since the in...

Roswell Park's Immunotherapy Center Produces Cancer Treatment Breakthroughs

Researchers with Roswell Park's Center for Immunotherapy are optimistic about a new approach that involves genetically arming stem cells that produce enhanced immune cells that can defend against cancer potentially for life. Since Roswell Park’s Center for Immunotherapy opened in 2009, researchers have produced several breakthroughs in cancer treatment. They include the SurVaxM vaccine to treat brain cancer (glioblastoma) that has shown promise in clinical trials. There is also the historic CimaVax trial now ongoing. That is a lung cancer vaccine that was developed in Cuba. Looking ahead, researchers are optimistic about a new approach that involves genetically arming stem cells that produce enhanced immune cells that can defend against cancer potentially for life. The FDA still needs to approve this trial, and Ride for Roswell funds are slated to support it. Source : https://goo.gl/Hwnmx4

Know About NIPAH Virus

Kerala is on high alert as the deadly virus called ‘NIPAH’ (NiV) which has already claimed 10 lives in the state including a nurse while providing care to infected patients. The worrying aspect of the virus is that it has a 70 % mortality rate, and causes severe diseases in both animals and humans. Nipah Virus infection in humans can exhibit itself in different forms, from showing no symptoms of infection (asymptomatic) to acute respiratory syndrome and lethal encephalitis. NIPAH virus was first identified in Malaysia and Singapore in 1998 and 1999. The pigs were the hosts of this virus but a fresh flare of Nipah Virus (NiV) has emerged in Kerala, in India where the hosts are fruit bats. Previous Outbreak in India: The disease was first reported in 2001 in Siliguri (West Bengal), claiming 45 lives out of 66 infected, and again six years later in 2007 in Nadia (West Bengal) where it claimed 5 lives out of 5 infected. What is Nipah Virus? Nipah virus (NiV) infection...